期刊文献+

HPV-DNA分型检测在宫颈病变筛查中的应用价值 被引量:4

Value of human papillomavirus genotype testing in screening of cervical lesions
下载PDF
导出
摘要 目的评价HPV-DNA分型检测在宫颈病变筛查中的应用价值。方法对200例细胞学筛查阳性病例进行阴道镜下多点取材活检及HPV分型检测。结果 HPV阳性121例,阳性率为60.50%;感染频度前5位依次为16、58、39、6、33型。宫颈细胞学检查异常HPV阳性确诊为CIN者73例,HPV阴性确诊CIN者13例,两者有统计学差异(χ2=50.96%,P<0.05)。细胞学诊断为ASC的病例中,HPV阳性组宫颈病变检出率(19/68)与阴性组(5/75)对比,两者有统计学差异(χ2=14.01,P<0.05)。结论 HPV分型检测对宫颈病变具有很高的敏感度和阴性预测值,在宫颈病变筛查及HPV疫苗研发中具有重要意义。 【Objective】To assess the value of human papillomavirus(HPV) genotype testing in screening of cervical lesions.【Methods】Two hundred cases of atypical squamous cells(ASC) or more severe than ASC lesions are classified into positive cytology.These cases were referred for biopsy and HPV genotype testing.【Results】Positive HPV testing appeared in 121 cases,positive rate was 60.50 %.The top five prevalent HPV types were type 16,58,39,6 and 33.Among these cases with definite diagnosis of CIN by biopsy,73 cases showed positive HPV testing,13 cases were HPV negative with statistic difference(χ2 =50.96%,P 0.05).Among these cases of atypical squamous cells(ASC),the rates of CIN in the group of positive HPV testing and in the group of negative were different in statistics(χ2 = 4.01,P 0.05).【Conclusion】HPV genotype testing has high sensitivity and negative-predictive value,and provides very useful information for the screening of cervical lesions and development of HPV vaccine.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2010年第6期865-867,871,共4页 China Journal of Modern Medicine
关键词 人乳头状瘤病毒(HPV) 宫颈病变 基因型 human papillomavirus(HPV) cervical lesion genotype
  • 相关文献

参考文献7

二级参考文献51

共引文献736

同被引文献29

  • 1彭莉,姚吉龙,徐波,覃春容.高级别CIN宫颈锥切术后切缘残留47例临床分析[J].肿瘤预防与治疗,2009,22(1):49-51. 被引量:8
  • 2林伟华,张晶.宫颈癌的预防及普查[J].中国实用医药,2007,2(32):148-149. 被引量:3
  • 3Madeddu G, Mameli G, Mura M, et al. HPV infection in I-IIV-positivefemales: the need for cervical cancer screening including HPV-DNA detection despite successful HAART [J]. Eur Rev Med Pharmacol Sci, 2014, 18(8):1277-1285.
  • 4Norman I, Hjerpe A, Andersson S. High-risk HPV L1 capsid protein as a marker of cervical intraepithelial neoplasia in high-risk HPV- positive women with minor cytological abnormalities [J ]. Oncol Rep, 2013, 30 ( 2 ) :695 -700.
  • 5Ronco G, Biggeri A, Giorgi-Rossi P, et al. Health technology assess- ment report: HPV DNA based primary screening for cervical cancer precursors [J ]. Epidemiol Prev, 2012, 36(3-4 Suppl l ):el-e72.
  • 6Kirschner B, Junge J, Schledermann D, et al. HPV genotypes in inva- sive cervical cancer in Danish women [J . Acta Obstet Gynecol Scand, 2013, 92(9):1023-1031.
  • 7Pileggi C, Flotta D, Bianco A, et al. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials [J]. ]nt J Cancer, 2014, 135( 1 ):166-177.
  • 8Kim J, Kim I, Ahn W, et al. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cer- vicography, as screening methods for the detection of uterine cervical cancer [J]. Oncol Rep, 2013, 29(4):1645-1651.
  • 9Zong J, Wang C, Xu X, et al. HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a can- didate therapeutic tumor vaccine [J]. Oncol Rep, 2013, 30(6): 3020-3026.
  • 10Wentzensen N, Sun C, Burk R, et al. Methylation of HPVI$, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3 [J]. J Natl Cancer Inst, 2012, 104(22):1738-1749.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部